Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Direxion Daily S&P 500 Bear 3X Shares ETF
SPXS
5
T-Rex 2x Inverse Tesla Daily Target ETF
TSLZ
US Stock MarketDetailed Quotes
SGMT Sagimet Biosciences
- 3.150
- +0.030+0.96%
Close Apr 25 16:00 ET
101.42MMarket Cap-2.17P/E (TTM)
3.228High3.000Low474.11KVolume3.120Open3.120Pre Close1.48MTurnover2.31%Turnover RatioLossP/E (Static)32.20MShares7.38052wk High0.65P/B64.55MFloat Cap1.73052wk Low--Dividend TTM20.49MShs Float20.710Historical High--Div YieldTTM7.30%Amplitude1.730Historical Low3.118Avg Price1Lot Size
About Sagimet Biosciences Company
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Company Profile
SymbolSGMT
Company NameSagimet Biosciences
Listing DateJul 14, 2023
Issue Price16.00
Founded2006
CEOMr. David Happel
MarketNASDAQ
Employees14
Fiscal Year Ends12-31
Address155 Bovet Road,Suite 303
CitySan Mateo
ProvinceCalifornia
CountryUnited States of America
Zip Code94402
Phone1-650-561-8600
Websitehttp://www.sagimet.com
Company Executives
- Name
- Position
- Salary
- David Happel
- President, Chief Executive Officer and Director
- 2.69M
- Elizabeth Rozek
- General Counsel and Chief Compliance Officer
- --
- Dr. Eduardo Bruno Martins, D.Phil.,M.D.
- Chief Medical Officer
- 1.51M
- Thierry Chauche
- Chief Financial Officer and Principal Accounting Officer
- --
- George Kemble, PhD
- Executive Chairman of the Board
- 930.22K
- Jennifer Ann Jarrett
- Independent Director
- --
- Elizabeth Grammer
- Independent Director
- 43.00K
- Timothy P. Walbert
- Independent Director
- --
- Dr. Merdad V. Parsey, M.D.,PhD
- Independent Director
- 41.50K
- Dr. Beth C. Seidenberg,M.D.
- Independent Director
- 14.38K
- Dr. Anne M. Phillips, M.D.
- Independent Director
- --
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
